Study of Sintlimab Maintenance Therapy in Patients With Extensive Small Cell Lung Cancer
Status:
Unknown status
Trial end date:
2021-05-31
Target enrollment:
Participant gender:
Summary
Small cell lung cancer is a highly aggressive malignancy. Currently, there is no effective
regimen for patients after the progression offirst-line chemotherapy. The prognosis of
patients with extensive disease is very poor, and the improved therapeutic efficacy is
urgently needed. Most patients with small cell lung cancer have a long history of smoking,
and the tumor mutation burden is relatively high, which provides potential for immunological
checkpoint inhibitors represented by PD-1 antibodies. A number of studies have shown that
chemotherapy combined with adoptive cellular immunotherapy could prolong the survival of
patients. This study is a clinical study to explore the efficacy and safety of maintenance
therapy with sintilimab after 4-6 cycles of first-line chemotherapy combined with adoptive
cellular immunotherapy in patients with advanced small cell lung cancer.